A valid prescription requires a telehealth consultation with a licensed provider. No medication is dispensed without clinical evaluation.

AOD-9604
Investigational C-Terminal Lipolytic Fragment


Compound Specifications
AOD-9604
Investigational C-Terminal Lipolytic Fragment
AOD-9604 is an investigational peptide fragment (amino acids 177-191) derived from human growth hormone. Laboratory and clinical research have explored its potential involvement in lipolytic pathways and lipid metabolism.
Studied in preclinical research for potential interactions with adipose cell receptors and lipid breakdown pathways without the broader somatogenic effects associated with full-length growth hormone.
Documented Therapeutic Benefits
Results may vary. Individual outcomes depend on adherence, baseline health, and other factors.
Subcutaneous injection daily, ideally prior to activity or fasting windows.
Frequently Asked Clinical Questions
Does AOD-9604 affect blood sugar like HGH?
Preclinical studies indicate AOD-9604 is an isolated fragment studied for lipid metabolism pathways without the somatogenic, diabetogenic, or IGF-1 elevating properties of full-length growth hormone.
Can AOD-9604 be stacked with other peptides?
Yes, it is frequently combined with MOTS-c, Tesamorelin, or GLP-1s for amplified metabolic and fat-loss synergy.
